LADENBURG THALM/SH SH Downgrades Bionano Genomics (NASDAQ:BNGO) to Neutral

LADENBURG THALM/SH SH downgraded shares of Bionano Genomics (NASDAQ:BNGO) from a buy rating to a neutral rating in a research report report published on Friday morning, MarketBeat.com reports.

A number of other equities analysts have also recently weighed in on BNGO. BTIG Research cut Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Tuesday, September 10th. Scotiabank reiterated a “sector perform” rating and set a $1.00 price target (down from $6.00) on shares of Bionano Genomics in a research report on Wednesday, August 28th.

Bionano Genomics Trading Down 3.8 %

Shares of BNGO stock traded down $0.01 during trading on Friday, hitting $0.25. 2,836,577 shares of the stock traded hands, compared to its average volume of 1,776,913. The firm has a market capitalization of $21.16 million, a P/E ratio of -0.05 and a beta of 2.37. Bionano Genomics has a 52-week low of $0.24 and a 52-week high of $2.27. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.63 and a quick ratio of 1.11. The firm’s fifty day moving average price is $0.36 and its 200-day moving average price is $0.60.

Hedge Funds Weigh In On Bionano Genomics

Several hedge funds have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in Bionano Genomics during the 1st quarter worth about $36,000. Price T Rowe Associates Inc. MD lifted its stake in Bionano Genomics by 123.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock worth $79,000 after acquiring an additional 38,900 shares in the last quarter. Carret Asset Management LLC lifted its stake in Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after acquiring an additional 40,055 shares in the last quarter. GSA Capital Partners LLP acquired a new position in Bionano Genomics during the 3rd quarter worth about $46,000. Finally, Cetera Advisors LLC acquired a new position in Bionano Genomics during the 1st quarter worth about $163,000. Institutional investors and hedge funds own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.